SVT-001

SVT-001 is an investigational cell-based regenerative therapy developed by Sanaregen Vision Therapeutics for the treatment of familial drusen, an inherited macular degeneration disorder also known as Doyne honeycomb retinal dystrophy or Malattia Leventinese. The therapy is designed to restore retinal function and improve vision in affected individuals. The FDA has cleared an Investigational New Drug (IND) application for SVT-001, enabling the initiation of a Phase I/II clinical trial to evaluate its safety and preliminary efficacy. As a regenerative treatment, it aims to address the vision loss associated with the accumulation of sub-retinal deposits characteristic of the condition. Detailed information regarding the specific cell type and manufacturing process remains proprietary.